Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease

J Neurol. 2019 May;266(5):1270-1271. doi: 10.1007/s00415-019-09257-5. Epub 2019 Feb 25.

Authors

Stephan Richter¹, Bert Wagner², Elisabeth Gulowsen Celius^{3

4}

Affiliations

¹ Neuro-MVZ (MIND) Stuttgart, Charlottenstrasse 14, 70182, Stuttgart, Germany. dr.richter@neuro-mvz.de.
² Neuro-MVZ (MIND) Stuttgart, Charlottenstrasse 14, 70182, Stuttgart, Germany.
³ Department of Neurology, Oslo University Hospital, 4956, 0424, Ullevål, Boks, Nydalen, Oslo, Norway.
⁴ Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

PMID: 30805797
DOI: 10.1007/s00415-019-09257-5

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Alemtuzumab / adverse effects*
Alemtuzumab / therapeutic use
Diabetes Mellitus, Type 1 / diagnosis
Diabetes Mellitus, Type 1 / etiology*
Diabetes Mellitus, Type 1 / immunology
Female
Humans
Immunologic Factors / adverse effects*
Immunologic Factors / therapeutic use
Male
Multiple Sclerosis, Relapsing-Remitting / therapy*

Substances

Immunologic Factors
Alemtuzumab